GSK plc (LSE/NYSE: GSK) announced that it has entered into a definitive agreement to acquire Affinivax, Inc. (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge, Boston, Massachusetts, for a $2.1 billion upfront payment and up to $1.2 billion in potential development milestones. Affinivax is pioneering the development of a novel class of vaccines, the most advanced of which are next-generation pneumococcal vaccines.
GSK to acquire clinical-stage biopharmaceutical company Affinivax, Inc.
June 2, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022